D. E. Shaw & Co., Inc. G1 Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in G1 Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 785,259 shares of GTHX stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

785,259

Previous 495,451 58.49%

Holding current value

$2.02 Million

Previous $1.51 Million 124.49%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.1 - $4.83 $608,596 - $1.4 Million	289,808 Added 58.49%	785,259 $3.39 Million
Q4 2023 Feb 14, 2024	SELL	$1.12 - $3.73 $10,786 - $35,923	-9,631 Reduced 1.91%	495,451 $1.51 Million
Q3 2023 Nov 14, 2023	SELL	$1.22 - $2.67 $135,933 - $297,494	-111,421 Reduced 18.07%	505,082 $727,000
Q2 2023 Aug 14, 2023	BUY	$2.46 - $3.14 $459,685 - $586,752	186,864 Added 43.49%	616,503 $1.54 Million
Q1 2023 May 15, 2023	SELL	$2.57 - $8.16 $38,724 - $122,954	-15,068 Reduced 3.39%	429,639 $1.15 Million

Q4 2022 Feb 14, 2023	BUY	$5.19 - $13.5 $1.82 Million - $4.72 Million	349,733 Added 368.24%	444,707 $2.41 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $16.99 $217,165 - $713,664	-42,005 Reduced 30.67%	94,974 $1.19 Million
Q2 2022 Aug 15, 2022	BUY	$4.04 - $8.51 $553,395 - $1.17 Million	136,979 New	136,979 $677,000
Q1 2021 May 17, 2021	SELL	$17.58 - $32.59 $307,034 - $569,184	-17,465 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$10.99 - $20.4 $191,940 - $356,286	17,465 New	17,465 $314,000
Q2 2020 Aug 14, 2020	SELL	$9.57 - $24.37 $490,778 - $1.25 Million	-51,283 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$9.07 - $26.32 $465,136 - $1.35 Million	51,283 New	51,283 $565,000

Others Institutions Holding GTHX

# of Institutions

Shares Held

14.7M

Call Options Held

631K

Put Options Held

347K

View Full List

About G1 Therapeutics, Inc.

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $110M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

More about GTHX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account